<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085306</url>
  </required_header>
  <id_info>
    <org_study_id>CASE1604</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CCF-4049</secondary_id>
    <secondary_id>CASE1604</secondary_id>
    <nct_id>NCT00085306</nct_id>
  </id_info>
  <brief_title>Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma</brief_title>
  <official_title>Phase II Trial Of Interferon-B In Patients With Metastatic Cutaneous Melanoma And Metastatic Ocular Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Interferon beta may interfere with the growth of tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well interferon beta works in treating patients&#xD;
      with metastatic cutaneous (skin) melanoma or ocular (eye) melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective clinical response rate in patients with metastatic cutaneous or&#xD;
           ocular melanoma treated with interferon beta.&#xD;
&#xD;
        -  Determine the frequency and degree of apoptosis induction in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study. Patients are stratified according to type of melanoma&#xD;
      (ocular vs cutaneous).&#xD;
&#xD;
      Patients receive interferon beta subcutaneously once daily in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed within 3 days after completion of study treatment and then for&#xD;
      survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28-56 patients (14-28 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective clinical response rate to IFN-B the maximum tolerated dose as measured by a CTC Grade III hematologic or a Grade IV granulocyte toxicity which persists &gt; 3 days at 1 week after each course</measure>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Stage IV Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <arm_group>
    <arm_group_label>Recombinant interferon beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon beta</intervention_name>
    <description>recombinant interferon beta</description>
    <arm_group_label>Recombinant interferon beta</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic melanoma&#xD;
&#xD;
               -  Cutaneous or ocular disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No active unstable CNS metastases by neurologic exam AND CT scan or MRI&#xD;
&#xD;
               -  Irradiated and/or resected CNS lesions allowed if there is no evidence of disease&#xD;
                  by head MRI or CT scan for &gt; 6 months after surgery and/or radiotherapy&#xD;
&#xD;
               -  Patients with cutaneous metastases and previously irradiated and/or resected CNS&#xD;
                  metastases are eligible if the CNS metastases are controlled and do not require&#xD;
                  dexamethasone&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1 (0-2 for patients with cutaneous metastases)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,200/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.5 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST ≤ 3.0 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times normal (10 times normal if due to bone metastases)&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris&#xD;
&#xD;
          -  No New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  No other severe cardiovascular disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 3 years except basal cell or squamous cell skin&#xD;
             cancer or carcinoma in situ of the uterine cervix&#xD;
&#xD;
          -  No history of seizure disorder&#xD;
&#xD;
          -  No severe psychiatric disorder&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 12 months since prior adjuvant interferon alfa-2 (IFNα-2) therapy&#xD;
&#xD;
          -  More than 30 days since prior IFNα-2 therapy for metastatic disease (6 months for&#xD;
             patients with cutaneous metastases)&#xD;
&#xD;
          -  No more than 1 prior systemic regimen (chemotherapy or biologic) for metastatic&#xD;
             disease (3 regimens for patients with cutaneous metastases)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Concurrent replacement therapy with physiologic doses of corticosteroids allowed&#xD;
&#xD;
               -  No concurrent dexamethasone or other steroidal antiemetics or anti-inflammatories&#xD;
&#xD;
          -  No other concurrent hormonal agents except steroids administered for preexisting&#xD;
             adrenal failure or hormones administered for non-disease-related conditions (e.g.,&#xD;
             insulin for diabetes)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 28 days since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent palliative radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  More than 28 days since prior major surgery requiring general anesthesia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 28 days since prior antibiotics for local or systemic infection&#xD;
&#xD;
          -  No concurrent aspirin&#xD;
&#xD;
          -  No concurrent barbiturates&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ernest C. Borden, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>iris melanoma</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

